Vir Biotechnology (VIR) Retained Earnings (2018 - 2026)

Vir Biotechnology has disclosed Retained Earnings across 9 years of filings, most recently posting -$1.3 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.3 billion, down 66910.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 66910.94% YoY), and the FY2025 annual result was -$1.2 billion, down 57.65% from the prior year.
• Retained Earnings came in at -$1.3 billion for Q1 2026 at Vir Biotechnology, down from -$1.2 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $478.8 million in Q3 2022 to a low of -$1.3 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$2.9 million (2023), against an average of -$230.1 million.
• Across the five-year window, Retained Earnings surged 36733.51% in 2022 and tumbled 93125.03% in 2024, its largest moves.
• Vir Biotechnology's Retained Earnings stood at $377.2 million in 2022, then slumped by 100.22% to -$815000.0 in 2023, then sank by 93125.03% to -$759.8 million in 2024, then plunged by 57.65% to -$1.2 billion in 2025, then dropped by 10.49% to -$1.3 billion in 2026.
• The last three Retained Earnings figures came in at -$1.3 billion (Q1 2026), -$1.2 billion (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.